Authors
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Who is Driving the HTA Bus? And Where is it Headed?An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.
Latest:
Who is Driving the HTA Bus? And Where is it Headed?An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.
Latest:
Who is Driving the HTA Bus? And Where is it Headed?An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.
Latest:
Who is Driving the HTA Bus? And Where is it Headed?An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.
Latest:
Who is Driving the HTA Bus? And Where is it Headed?An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.
Latest:
Lay the Tech Foundation for IPO SuccessMike Kean and Billy Tamulynas discuss the key components of growth-ready technology for early-stage pharma companies and how to make optimal use of them.
Latest:
Driving Success in Gene TherapyGetting real about the R&D capabilities required to win in the gene therapy space.
Latest:
Driving Success in Gene TherapyGetting real about the R&D capabilities required to win in the gene therapy space.
Latest:
Value-Based Planning Uncovers True Drivers of Cost Across Life Sciences OrganizationsExplicitly tying strategic planning to resource allocation boosts bottom-line productivity for pharma.
Latest:
Driving Success in Gene TherapyGetting real about the R&D capabilities required to win in the gene therapy space.
Latest:
Driving Success in Gene TherapyGetting real about the R&D capabilities required to win in the gene therapy space.
Latest:
AI in the R&D Value ChainIn comparison with other industries, the use of AI is modest in life sciences. However, even within life sciences, adoption of AI in regulated environments, such as in the R&D value chain, is further behind. Sivakumar Thiagarajan
Latest:
Emerging Pharma Must Pick Up Pace in Analytics Arms RaceMost emerging pharma companies still struggle to amass the computing power and assemble the teams to make use of the vast amounts of data now available to them, write Beth Beghou and Patrick Lezark.
Latest:
Navigating AMCP’s New Formulary Updatesreviews the two most salient changes in Academy of Managed Care Pharmacy's new Format for Formulary Submissions
Latest:
Leading Integration: Six Steps to Preserve Acquisition ValueHealthy companies with coherent integration strategies will benefit from applying six lessons to ensure successful integration, writes Mark Bouch.
Latest:
Integrated Scientific Advice: Helping to Optimize RWE Planning for Market AccessA review of the current use of real-world data and evidence in HTA and payer appraisals, its potential role in lifecycle management, and how the early dialogue provided by Integrated Scientific Advice engagement can be used as a key tool in the planning and generation of RWE.
Latest:
Marketing to HCPs in the New World OrderThe current COVID-19 pandemic has taken the world of HCP marketing and turned it upside down. Biopharma has had to make instantaneous decisions on how to market in this new environment, who to market to, which tactics to significantly increase, and which tactics to walk away from-all with no historical playbook.
Latest:
FDA’s Generic Drug Program Offers Assistance, Resources For ANDA ApplicantsA look at how to develop a generic drug and the resources FDA supplies to Abbreviated New Drug Application applications.
Latest:
FDA’s Generic Drug Program Offers Assistance, Resources For ANDA ApplicantsA look at how to develop a generic drug and the resources FDA supplies to Abbreviated New Drug Application applications.
Latest:
A Meaningful Customer-Centric Digital StrategyWithout a clear, customer-centric digital experience at the core of every brand, it is impossible to deliver on the brand promise at scale, write Dr. Pamela Walker and Tom Murdoch.
Latest:
Trends in Payer Reliance on ICER AssessmentsIn response to growing Institute for Clinical and Economic Review (ICER) activity, Jenny Lee and Eric Latch take a revised look at payer reliance on ICER assessments and perceptions on value-based pricing.
Latest:
Revamping Internship Programs for a Virtual WorldA look at how internship programs in the pharma industry have changed since the start of the COVID-19 pandemic.
Latest:
Uncover Potential Life Cycle Opportunities in Oncology Using Patient-Centric OutcomesFocusing on prevention, diagnosis, treatment, and care monitoring during the patient journey in oncology to create value for stakeholders.
Latest:
Rethinking Unmet Patient Medical Needs Through the Lens of the Patient JourneyBiopharma companies can foster patient-centered innovation by focusing on unmet needs along each stage of the patient journey while collaborating with key stakeholders directly or indirectly responsible for disease management.
Latest:
Maximize New Product Potential Through Early Commercial PlanningFive key areas biopharma manufacturers focus on to predict where the markets will be and determine how standards of care will evolve to effectively position new products.
Latest:
Can Global Innovation in Oncology be Sustained in the Face of Price Controls?Pricing in the context of patient access and affordability continues to present problems and constitute a real threat to innovation. Meaningful reform involves rectifying market imperfections in public and private third-party prescription drug payment sectors, writes Robert A. Freeman.
